NKTX: Nkarta, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
135 institutions reported holding $162.35M of Nkarta, Inc. on Form 13F (126 the quarter before). 25 opened a new position and 13 sold out. Shares held by institutions: +2%.
| Largest holders | Shares | Value |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10,805,129 | $30.58M |
| BlackRock, Inc. | 6,300,212 | $17.83M |
| NEA Management Company, LLC | 3,568,781 | $10.10M |
| SAMSARA BIOCAPITAL, LLC | 3,507,666 | $9.93M |
| SR One Capital Management, LP | 3,333,333 | $9.43M |
| GSK plc | 3,150,732 | $8.92M |
| Monaco Asset Management SAM | 2,373,400 | $6.72M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,226,415 | $6.30M |
| CITADEL ADVISORS LLC | 2,174,745 | $6.15M |
| TWO SIGMA INVESTMENTS, LP | 1,873,293 | $5.30M |
Clinical trial readouts
1 Phase 2 or 3 trials by Nkarta, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-04 (est.) | NKX019 | Lupus Nephritis | Phase 1/2 | 120 | Recruiting | NCT06557265 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.